{"id":203200,"date":"2026-04-08T08:30:00","date_gmt":"2026-04-08T12:30:00","guid":{"rendered":"https:\/\/testing.news-you-need.com\/index.php\/2026\/04\/08\/caris-life-sciences-introduces-multimodal-ai-powered-molecular-insight-to-identify-the-benefit-or-harm-from-the-addition-of-chemotherapy-for-nsclc-patients\/"},"modified":"2026-04-08T08:50:14","modified_gmt":"2026-04-08T12:50:14","slug":"caris-life-sciences-introduces-multimodal-ai-powered-molecular-insight-to-identify-the-benefit-or-harm-from-the-addition-of-chemotherapy-for-nsclc-patients","status":"publish","type":"post","link":"https:\/\/testing.news-you-need.com\/index.php\/2026\/04\/08\/caris-life-sciences-introduces-multimodal-ai-powered-molecular-insight-to-identify-the-benefit-or-harm-from-the-addition-of-chemotherapy-for-nsclc-patients\/","title":{"rendered":"Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients"},"content":{"rendered":"<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/caris-life-sciences-introduces-multimodal-ai-powered-molecular-insight-to-identify-the-benefit-or-harm-from-the-addition-of-chemotherapy-for-nsclc-patients-302736578.html\">Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients<\/a><\/p>\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/caris-life-sciences-introduces-multimodal-ai-powered-molecular-insight-to-identify-the-benefit-or-harm-from-the-addition-of-chemotherapy-for-nsclc-patients-302736578.html\">https:\/\/www.prnewswire.com\/news-releases\/caris-life-sciences-introduces-multimodal-ai-powered-molecular-insight-to-identify-the-benefit-or-harm-from-the-addition-of-chemotherapy-for-nsclc-patients-302736578.html<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-04-08 08:30:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.prnewswire.com\">www.prnewswire.com<\/a><\/p>\n<ul>\n<li>\n<p><strong>Innovative AI-Driven Molecular Insight:<\/strong> Caris Life Sciences launched an AI-driven molecular insight for non-small cell lung cancer (NSCLC) patients to determine who may benefit from chemotherapy alongside immunotherapy.<\/p>\n<\/li>\n<li>\n<p><strong>Precision Oncology Advancements:<\/strong> The company applies its proprietary CodeAI\u2122 platform to integrate multiple real-world datasets, enhancing precision oncology through comprehensive molecular profiling via sequencing technologies.<\/p>\n<\/li>\n<li>\n<p><strong>Improved Treatment Decisions:<\/strong> The new signature, developed from large-scale clinico-genomic datasets, identifies molecular signatures linked to treatment response, aiding personalized therapy choices for NSCLC patients.<\/p>\n<\/li>\n<li>\n<p><strong>Reduction in Unnecessary Chemotherapy:<\/strong> The AI model aims to help avoid subjects to chemotherapy that could be harmful, thereby improving patient care and outcomes in lung cancer treatment.<\/p>\n<\/li>\n<li>\n<p><strong>FDA-Approved Molecular Profiling Assay:<\/strong> Caris received FDA approval for MI Cancer Seek, the only simultaneous WES and WTS-based assay with companion diagnostic indications for solid tumor profiling.<\/p>\n<\/li>\n<\/ul>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":203201,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/mma.prnewswire.com\/media\/830740\/Caris_Life_Sciences_Logo.jpg?p=facebook","fifu_image_alt":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-203200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence"],"_links":{"self":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/203200"}],"collection":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=203200"}],"version-history":[{"count":1,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/203200\/revisions"}],"predecessor-version":[{"id":203202,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/203200\/revisions\/203202"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/203201"}],"wp:attachment":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=203200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=203200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=203200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}